Can Anti-Inflammatories Slow Myopia?

• by Jody Summers , R. Michael Siatkowski

• September 21, 2026

Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.

• by Andrea Surnit

• July 8, 2026

• 3 min

Procedural Pharmaceutical Lessons From Early Adopters

Experienced glaucoma surgeons share practical pearls on integrating sustained drug delivery into practice.

• by Christine Funke, MD, J. Morgan Micheletti, MD, FACS, Jason Bacharach, MD, Shivani S. Kamat, MD, Arkadiy Yadgarov, MD, Steven R. Sarkisian, Jr., MD, Robert F. Melendez, MD, MBA, Syril K. Dorairaj, MD, and, Pranav Vasu, MPH, Savak “Sev” Teymoorian, MD, MBA, Reza Alizadeh, MD, Lorraine M. Provencher, MD, Jai G. Parekh, MD, MBA, FAAO, Manjool Shah, MD, Inder Paul Singh, MD, Huda Sheheitli, MD, Reena A. Garg, MD, Zarmeena Vendal, MD

• September 1, 2026

• 18 min

Perspectives on Medicare’s Proposed iDose TR Coverage Policy

In May 2026, 5 Medicare Administrative Contractors released proposed Local Coverage Determinations (LCDs) addressing Medicare reimbursement for anterior-segment intraocular nonbiodegradable drug-eluting systems, a category that currently includes only the travoprost intracameral implant iDose TR (Glaukos). Glaucoma Physician spoke with several leading surgeons who expressed concerns about the proposed LCDs and suggested changes they believe would better reflect contemporary glaucoma practice.

• by Steven R. Sarkisian, Jr., MD, Inder Paul Singh, MD, Savak “Sev” Teymoorian, MD, MBA, Manjool Shah, MD, Christine Funke, MD, Philip S. Garza, MD, MSc

• September 1, 2026

• 10 min